HomeInsightsStock Comparison

Accretion Pharmaceuticals Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Accretion Pharmaceuticals Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Last Updated on: Jun 06, 2025

Key Highlights

  • The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 65.4 as of 06 Jun 15:30.
  • The P/E Ratio of Accretion Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 82.8 on March 2020 to 82.4 on March 2024 . This represents a CAGR of -0.10% over 5 years.
  • The Market Cap of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 5978 crore on March 2020 to ₹ 13301 crore on March 2024 . This represents a CAGR of 17.34% over 5 years.
  • The revenue of Accretion Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 496.63 crore as compare to the Dec '24 revenue of ₹ 448.27 crore. This represent the growth of 10.79%.
  • The ebitda of Accretion Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 96.84 crore as compare to the Dec '24 ebitda of ₹ 51.42 crore. This represent the growth of 88.33%.
  • The net profit of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 53.86 crore to ₹ 58.25 crore over 8 quarters. This represents a CAGR of 4.00% .
  • The Dividend Payout of Accretion Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Accretion Pharmaceuticals Ltd

  • Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
  • Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in year 2014.
  • Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

Accretion Pharmaceuticals Ltd News Hub

News

Accretion Pharmaceuticals to discuss results

Accretion Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

05 Jun 2025 10:16

News

NSE SME Accretion Pharma stumbles on market debut

The scrip was listed at 79, a discount of 21.78% over the initial public offer (IPO) price...

Read more

21 May 2025 10:38

News

NSE SME Accretion Pharmaceuticals' IPO ends with subscription of 7.31 times

The initial public offer (IPO) of Accretion Pharmaceuticals received bids for 2,00,06,400 ...

Read more

19 May 2025 11:43

Astrazeneca Pharma India Ltd News Hub

News

Astrazeneca Pharma India Ltd Spurts 7.28%

Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare ...

Read more

02 Jun 2025 09:30

News

AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up...

Read more

02 Jun 2025 10:10

News

Volumes soar at Astrazeneca Pharma India Ltd counter

Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas ...

Read more

02 Jun 2025 11:00

News

Astrazeneca Pharma India Ltd leads gainers in 'A' group

Sun Pharma Advanced Research Company Ltd, Bank of Maharashtra, Reliance Power Ltd and Genu...

Read more

02 Jun 2025 12:00

News

Volumes spurt at Astrazeneca Pharma India Ltd counter

Niva Bupa Health Insurance Company Ltd, Indian Overseas Bank, Sterling & Wilson Renewable ...

Read more

02 Jun 2025 14:30

News

AstraZeneca Pharma receives marketing approval for Benralizumab in India

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control O...

Read more

30 May 2025 09:16

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of null and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Astrazeneca Pharma India Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 72 Cr while Market cap of Astrazeneca Pharma India Ltd is 24,479 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Astrazeneca Pharma India Ltd?

As of June 6, 2025, the Accretion Pharmaceuticals Ltd stock price is INR ₹65.4. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹9791.9.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions